AKT1 and cancer: Until now, a variety of signaling pathways has been revealed as the downstream targets of CD147 in diverse cancers, such as the Akt/mTOR/SREBP1c pathway in hepatocellular carcinoma [17], β-TrCP/Nrf2 pathway in glioma [33], MEK pathway in hypopharyngeal squamous cell carcinoma [34], JAK/STAT pathway in breast cancer [35], and NF-kB pathway in head and neck squamous cell carcinoma [36].